LGVN
Longeveron Inc. Common Stock
Nasdaq · usd
Longeveron Inc. Common Stock (LGVN) trades at $2.48 (+23.38%) as of 11:35:48 AM EST on Nov 10, 2026, +0.82% over the past month. Market cap is $6.41M, with 1.0 days to cover in short interest.
Stock performance
How Longeveron Inc. Common Stock (LGVN) stock has performed from one day to one year, with its 52-week range.
- 1D
- +22.89%
- 1W
- +38.76%
- 1M
- +0.82%
- YTD
- -51.19%
- 1Y
- -65.56%
- 52-wk range
- $1.31 – $12.30
Key statistics
Today's trading snapshot for LGVN: day range, open, previous close, volume and market cap.
- Day range
- $1.98 – $2.54
- Open
- $2.08
- Prev close
- $2.01
- Volume
- 120.87K
- Market cap
- $6.41M
- Shares out
- 3.04M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Longeveron Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 5.40
- P/B
- 0.62
- P/FCF
- —
- ROE
- -225.7%
- ROA
- -151.6%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 9, 2026
8-K filings
Material corporate events Longeveron Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Director departureNov 5, 2026
On November 1, 2026, Ms. Ursula Ungaro provided Longeveron Inc. (the "Company") with notice of her immediate resignation from the Company's Board of Directors and its Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Special Committee. Ms. Ungaro indicated that her decision to resign was due to personal health issues and not the result of any disagreement with the Company on any matter related to the Company's operations, policies, or practices.
- Clinical trial resultsOct 26, 2026
Longeveron Inc. issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary efficacy endpoint, but the secondary endpoint analysis showed eight major adverse cardiac events in the standard-of-care arm versus one in the laromestrocel arm (P=0.043).
- Executive officer departureOct 14, 2026
On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.
- Clinical trial resultsSep 23, 2026
On September 16, 2026, Longeveron Inc. issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating the Company's investigational stem cell therapy, laromestrocel, as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome ("HLHS"). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction ("RVEF") at Month 12.
- Listing compliance regainedSep 14, 2026
On September 11, 2026, the Company received written notification from Nasdaq indicating that the Company's Common Stock had a closing price of $1.00 per share or greater for the last 10 consecutive business days, from August 27, 2026 until September 10, 2026, and that, as a result, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.
Dividend history and stock splits
Longeveron Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-10Aug 27, 2026
- 1-for-10Mar 27, 2024
LGVN short interest
How heavily LGVN is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.0
- Short interest
- 73.18K
- Avg volume
- 73.33K
As of · reported to FINRA twice monthly.
LGVN news
The latest news and headlines about Longeveron Inc. Common Stock (LGVN).
- Longeveron Announces 1-for-10 Reverse Stock SplitneutralGlobeNewswire Inc.· Aug 24, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellspositiveBenzinga· Apr 10, 2026
- A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.positiveBenzinga· Mar 18, 2026
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThempositiveBenzinga· Mar 3, 2026
- Longeveron Announces Closing Of Up To $17.5 Million Public OfferingneutralBenzinga· Aug 11, 2025
Frequently asked questions
What is the Longeveron Inc. Common Stock (LGVN) stock price today?
Longeveron Inc. Common Stock (LGVN) is trading at $2.48 (+23.38% on the day) as of 11:35:48 AM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Longeveron Inc. Common Stock?
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel.
What is the short interest in LGVN?
As of Oct 15, 2026, LGVN has 73.18K shares short and 1.0 days to cover.
What exchange is LGVN listed on?
Longeveron Inc. Common Stock (LGVN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of LGVN with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a LGVN analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.